TY - JOUR
T1 - Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAIL-mediated apoptosis
AU - Garnett, T. O.
AU - Filippova, M.
AU - Duerksen-Hughes, P. J.
N1 - Funding Information:
This work was supported in part by NIH Grant 1 R01 CA-095461 (PDH), Ruth L. Kirschstein National Service Award Individual Fellowship 1 F31 CA113650-01A1 (TG), and by NIH award 2R25 GM060507-05 (TG). In addition, we thank Dr. Carl Ware (La Jolla Institute for Allergy and Immunology) for the pcDNA-FADD-encoding plasmid.
PY - 2006/11
Y1 - 2006/11
N2 - Viruses have developed sophisticated strategies to evade host defenses and facilitate the production and spread of progeny. In this study, we show that transfection of the human papillomavirus (HPV) 16 E6 oncogene into HCT116 cells provides protection from tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-mediated apoptosis. Additionally, we demonstrate that the protection provided by E6 is dose-dependent because higher levels of E6 provide greater protection. The mechanism underlying this protection involves a rapid reduction in the protein levels of both Fas-associated death domain (FADD) and procaspase 8, which results in suppression of the activation of caspases 8, 3 and 2. Interestingly, E6 does not interfere with the mitochondrial apoptotic pathway even though HCT116 cells have been classified as type II cells with regard to TRAIL signaling. These findings demonstrate that E6 has a more generalized effect on signaling by death ligands than was previously thought and support the notion that E6 can utilize p53-independent mechanisms to modulate cell survival.
AB - Viruses have developed sophisticated strategies to evade host defenses and facilitate the production and spread of progeny. In this study, we show that transfection of the human papillomavirus (HPV) 16 E6 oncogene into HCT116 cells provides protection from tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-mediated apoptosis. Additionally, we demonstrate that the protection provided by E6 is dose-dependent because higher levels of E6 provide greater protection. The mechanism underlying this protection involves a rapid reduction in the protein levels of both Fas-associated death domain (FADD) and procaspase 8, which results in suppression of the activation of caspases 8, 3 and 2. Interestingly, E6 does not interfere with the mitochondrial apoptotic pathway even though HCT116 cells have been classified as type II cells with regard to TRAIL signaling. These findings demonstrate that E6 has a more generalized effect on signaling by death ligands than was previously thought and support the notion that E6 can utilize p53-independent mechanisms to modulate cell survival.
UR - https://www.scopus.com/pages/publications/33749617478
UR - https://www.scopus.com/pages/publications/33749617478#tab=citedBy
U2 - 10.1038/sj.cdd.4401886
DO - 10.1038/sj.cdd.4401886
M3 - Article
C2 - 16528386
SN - 1350-9047
VL - 13
SP - 1915
EP - 1926
JO - Cell Death and Differentiation
JF - Cell Death and Differentiation
IS - 11
ER -